Instil Bio, Inc. TIL
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-03-19 |
| Shares Out. | 6,780,000 |
| Website | instilbio.com ↗ |
| Phone | 13025310855 |
| Employees | 17 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$4.3M |
| Free Cash Flow | -$23.6M |
| Total Assets | $197.7M |
| Total Liabilities | $90.3M |
| Equity | $107.4M |
About Instil Bio, Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Instil Bio, Inc. is a publicly traded company under the ticker symbol TIL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-11-01)